March 12, 2008 / 5:50 PM / 11 years ago

US FDA panel backs Amgen's Nplate against ITP

GAITHERSBURG, Md., March 12 (Reuters) - A U.S. advisory panel urged regulators on Wednesday to approve an Amgen Inc (AMGN.O) drug for a rare disorder that puts patients at risk of serious bleeding.

The Food and Drug Administration advisers said the benefits of the injectable drug, called Nplate, outweighed the risks for treating chronic immune thrombocytopenia purpura (ITP). (Reporting by Lisa Richwine, editing by Gerald E. McCormick)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below